Data Detection Technologies Ltd v Doytec Automation Ltd UPC_CFI_554/2024

​
May 23, 2025

Order of 25 September 2024 [1]

This Order to Preserve Evidence pursuant to Art. 60 UPCA concerns a machine manufactured by the defendant that was being displayed at a 3-day trade fair. The application was made on day 2 of the trade fair and was referred to the standing judge, as is the case for extremely urgent matters. Although the application was filed before The Hague Local Division, the standing judge in this case was from the Local Division in Milan.

Data Detection Technologies Ltd. ("DDT", the applicant) is a manufacturer of "advanced counting and packaging solutions". DDT is the proprietor of EP2569713 ("EP713", the patent at issue) titled "Method and Apparatus for Dispensing Items". EP713 includes two independent claims: claim 1 relates a method for dispensing a predetermined number of discrete items into containers and claim 8 relates to an item dispenser as such. EP713 is a European patent which is validated nationally in 9 contracting states of the EPC, including the Netherlands.

Doytec Automation Ltd ("Doytec", the defendant) is a China-based manufacturer of equipment for automated counting, weighing and packing, in particular for seeds and beans.

Suspicion of Infringement

Both DDT and Doytec were exhibiting at the trade fair "Seeds meets Technology 2024" which took place from 24-26 September 2024 in Zwaagdijk-Oost, Netherlands. DDT's suspicions that Doytec was infringing EP713 arose as a result of two of DDT's employees' interactions with Doytec on the first day of the fair. The first employee observed a seed counting machine, called "C-1012", on display at Doytec's stand which they considered to be similar to the patented device made and sold by DDT. The second employee had a conversation with a Doytec representative who described a counting machine sold by the company possessing certain features of the claims of EP713.

In its application, DDT requested for the C-1012 (and related technical documentation) to be physically seized as a sample, and for a detailed description to be made by an independent expert.

Reasonably Available Evidence

Under Art. 60(1) UPCA, the court may order for the preservation of evidence if the applicant presents "reasonably available evidence to support the claim that the patent has been infringed or is about to be infringed". Developing case law of the UPC suggests that the bar for evidence is a fairly low one. This is perhaps unsurprising given that the filing of an evidence preservation application implies that the applicant needs to obtain further evidence of infringement before starting proceedings on the merits. The presence of certain (but not all) claimed features,[2] or a similarity of the alleged infringing product with the patented product sold by the applicant,[3] have both previously been deemed sufficient to satisfy this evidence requirement.

In support of DDT's application, the two employees provided written statements which included a summary of the features of the granted claims that they understood to be present in the C-1012, along with photos of the machine taken at the trade fair. The standing judge decided that infringement was "plausible" on the basis of this evidence. The evidence therefore supported DDT's claim that the patent was being infringed, but the judge noted that further evidence would be needed to prove the alleged infringement more conclusively.

Urgency and Risk of Destruction of Evidence

The court may order preservation of evidence without the other party (Doytec in this case) being heard "where there is a demonstrable risk of evidence being destroyed" (R197.1 RoP). The court took the view that the matter was extremely urgent, because the trade fair ended the following day and Doytec is a Chinese manufacturer, so there was a likelihood that the evidence would at least cease to be available in Europe after the trade fair.

As a result, the measures were ordered without Doytec being heard. Additionally, in accordance with R197.2 RoP, Doytec was not given prior notice of the measures. This is intended to (as the court put it in this case) "ensure the surprise effect" and prevent destruction of the evidence by the defendant before it can be seized.

When an order to preserve evidence is made without the defendant being heard, the applicant is required to provide security (to cover the defendant's legal costs, expenses or injury as a result of the order), "unless there are special circumstances not to do so" (R196.6 RoP). In this case, the court considered the extreme urgency to amount to special circumstances, as the time taken for DDT to provide security might lead to the evidence becoming unavailable. As DDT was a large company that would presumably have the means to bear the defendant's costs, provision of security by DDT was not required.

Confidentiality

An order to preserve evidence under Art. 60 UPCA is "subject to the protection of confidential information". Whilst the order can be made without the defendant being heard or given prior notice, the evidence is seized by an independent expert and is not immediately made available to the applicant. In this case, the measures were to be carried out by a Dutch patent attorney, assisted by a bailiff, and the evidence and report delivered to the Hague Local Division (where the application was filed).

The Court of Appeal has previously clarified that an application to preserve evidence "implies a request to disclose to the applicant the outcome of the measures", but in order to protect confidential information, the defendant should be given an opportunity to comment on the extent of the disclosure to the applicant.[4] In this case, Doytec was given until 30 October 2024 (around 1 month after delivery of the report to the Local Division) to file a request for confidentiality. If no such request was filed, the report would then become fully available to the applicant. This is different from the deadline for requesting a review of the order, which is 30 days from execution of the measures (R197.3 RoP).

Summary

Observations made by DDT employees at the trade fair suggested infringement was at least plausible, and no further evidence was required. The short duration of the trade fair and the fact that Doytec is an overseas company meant that there was extreme urgency and a risk that evidence could be destroyed or cease to be available. As a result, the measures were ordered immediately, without Doytec being heard and without the DDT providing security. This decision highlights the speed at which an evidence preservation order can be granted under extremely urgent circumstances, with the application filed and the measures ordered on the same day.

[1] The Order: https://www.unified-patent-court.org/en/node/97008

[2] Maguin SAS vs. Tiru, UPC_CFI_813/2024: https://www.unified-patent-court.org/en/node/69098

[3] Novawell v C-Kore System Ltd, UPC_CFI_397/2023: https://www.unified-patent-court.org/en/node/523

[4] Progress Maschinen & Automation AG v. AWM Srl & Schnell S.p.A, UPC_CoA_177/2024: https://www.unified-patent-court.org/en/node/936

The Latest Thought Leadership pieces in the Content Hub

Lionra Technologies Ltd. v Cisco Systems GmbH and Cisco Systems, Inc.
June 25, 2025
UPC_CFI_58/2024 Following a decision, a successful party has one month to apply for a costs decision (Rule 151). In the relevant case, the main decision (dated 19 February 2025) stated that the...
Provisional Injunction Denied for Small Molecule Kinase Inhibitor
June 19, 2025
Zentiva Portugal, LDA v. Boehringer Ingelheim International GMBH (UPC_CFI_41/2025 relating to EP1830843) Court of First Instance Order dated 8 May 2025 ORD_18599/2025 [1] Summary The Application for...
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​